Progress in the new nonnucleoside anti-HIV reverse transcriptase inhibitor-DCK.
- Author:
Huan-fang GUO
1
;
Lan XIE
Author Information
1. Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Anti-HIV Agents;
chemical synthesis;
chemistry;
pharmacology;
Biological Availability;
Camphor;
analogs & derivatives;
chemical synthesis;
chemistry;
pharmacology;
Coumarins;
chemical synthesis;
chemistry;
pharmacology;
HIV;
drug effects;
HIV Reverse Transcriptase;
antagonists & inhibitors;
Humans;
Lactones;
chemical synthesis;
chemistry;
pharmacology;
Structure-Activity Relationship
- From:
Acta Pharmaceutica Sinica
2008;43(10):997-1002
- CountryChina
- Language:Chinese
-
Abstract:
3',4'-Di-O-(S)-comphanoyl-(+)-cis-khellactone (DCK) is a synthetic khellactone ester that exhibits potent anti-HIV activity with a mechanism distinct from clinically used anti-HIV agents. Several series of DCK analoges have been synthesized and evaluated for inhibitory effects against HIV. This review article describes recent progress in the discovery, structural modification, and structure-activity relationship studies of potent anti-HIV DCK derivatives.
